{"filing":{"accession_number":"0001193125-26-238059","cik":"0001595097","ticker":"CRBP","company_name":"Corbus Pharmaceuticals Holdings, Inc.","form":"8-K","filing_date":"2026-05-26","report_date":null,"primary_document":"crbp-20260526.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1595097/000119312526238059/crbp-20260526.htm"},"events":[{"id":9013,"run_id":7911,"accession_number":"0001193125-26-238059","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.74,"summary":"Corbus Pharmaceuticals disclosed updated Phase 1/2 clinical data for CRB-701 (SYS6002), a Nectin-4 targeted ADC, demonstrating robust activity in oropharyngeal squamous cell carcinoma (OPSCC) and cervical cancer, with results to be presented at ASCO 2026 and FDA alignment on registrational trial designs.","company_name":"Corbus Pharmaceuticals Holdings, Inc.","ticker":"CRBP","filing_date":"2026-05-26","form":"8-K","submitted_at":null,"items":[{"id":1490,"accession_number":"0001193125-26-238059","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Corbus Pharmaceuticals disclosed updated Phase 1/2 clinical data for CRB-701 (SYS6002), a Nectin-4 targeted ADC showing \"robust activity\" in OPSCC and cervical cancer, to be presented at ASCO 2026. For a clinical-stage or early-commercial biopharmaceutical company, positive clinical data announcements are material to investor assessment of pipeline value and development progress. While this does not fit the more specific event categories (not an earnings release, M\u0026A, impairment, or litigation), the disclosure of meaningful clinical efficacy data for a lead program is material and warrants classification as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-27T02:10:52.157327+00:00","company_name":"","ticker":null,"filing_date":""},{"id":1491,"accession_number":"0001193125-26-238059","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The disclosure reports updated Phase 1/2 clinical trial data for CRB-701 showing efficacy and safety results in OPSCC and cervical cancer, along with FDA alignment on registrational trial designs. While this is a material clinical development milestone for a biopharmaceutical company that would affect investor assessment of pipeline progress and regulatory pathway, it does not fit neatly into the more specific event categories (e.g., it is not a restatement, impairment, litigation, or M\u0026A activity). The announcement of positive clinical data and regulatory alignment represents a significant positive development but is best classified as other_material given the taxonomy constraints.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-27T02:10:52.157327+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":1490,"accession_number":"0001193125-26-238059","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Corbus Pharmaceuticals disclosed updated Phase 1/2 clinical data for CRB-701 (SYS6002), a Nectin-4 targeted ADC showing \"robust activity\" in OPSCC and cervical cancer, to be presented at ASCO 2026. For a clinical-stage or early-commercial biopharmaceutical company, positive clinical data announcements are material to investor assessment of pipeline value and development progress. While this does not fit the more specific event categories (not an earnings release, M\u0026A, impairment, or litigation), the disclosure of meaningful clinical efficacy data for a lead program is material and warrants classification as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-27T02:10:52.157327+00:00","company_name":"Corbus Pharmaceuticals Holdings, Inc.","ticker":"CRBP","filing_date":"2026-05-26"},{"id":1491,"accession_number":"0001193125-26-238059","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The disclosure reports updated Phase 1/2 clinical trial data for CRB-701 showing efficacy and safety results in OPSCC and cervical cancer, along with FDA alignment on registrational trial designs. While this is a material clinical development milestone for a biopharmaceutical company that would affect investor assessment of pipeline progress and regulatory pathway, it does not fit neatly into the more specific event categories (e.g., it is not a restatement, impairment, litigation, or M\u0026A activity). The announcement of positive clinical data and regulatory alignment represents a significant positive development but is best classified as other_material given the taxonomy constraints.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-27T02:10:52.157327+00:00","company_name":"Corbus Pharmaceuticals Holdings, Inc.","ticker":"CRBP","filing_date":"2026-05-26"}]}